<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="503">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05154604</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-A1921-I-101</org_study_id>
    <nct_id>NCT05154604</nct_id>
  </id_info>
  <brief_title>A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours</brief_title>
  <official_title>A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1921 in Subjects With Advanced Malignant Solid Tumour .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours,&#xD;
      to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or&#xD;
      recommended phase II dose (RP2D) of SHR-A1921&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limited Toxicity (DLT)</measure>
    <time_frame>21 Days (first cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerable Dose (MTD)</measure>
    <time_frame>21 Days (first cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II dose (RP2D)</measure>
    <time_frame>Screening up to dose escalation and expansion study completion, appropriately to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Screening up to study completion, an average of 1 year</time_frame>
    <description>Incidence and grade of adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (Tmax) of SHR-A1921、total antibody</measure>
    <time_frame>Screening up to end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of SHR-A1921、total antibody</measure>
    <time_frame>Screening up to end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable time point t (AUC0-t) of SHR-A1921、total antibody</measure>
    <time_frame>Screening up to end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-t) of SHR-A1921、total antibody</measure>
    <time_frame>Screening up to end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of SHR-A1921、total antibody</measure>
    <time_frame>Screening up to end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CL) of SHR-A1921、total antibody</measure>
    <time_frame>Screening up to end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) of SHR-A1921、total antibody</measure>
    <time_frame>Screening up to end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT) of SHR-A1921、total antibody</measure>
    <time_frame>Screening up to end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum steady-state drug concentration during a dosage interval (Css, max) of SHR-A1921、total antibody</measure>
    <time_frame>Screening up to end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum steady-state drug concentration during a dosage interval (Css, min) of SHR-A1921、total antibody</measure>
    <time_frame>Screening up to end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) of SHR-A1921、total antibody</measure>
    <time_frame>Screening up to end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody(ADA) level of SHR-A1921</measure>
    <time_frame>Screening up to 90 days after the last dose, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) assessed by site investigator as per RECIST 1.1</measure>
    <time_frame>Screening up to study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) assessed by site investigator as per RECIST 1.1</measure>
    <time_frame>Screening up to study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) assessed by site investigator as per RECIST 1.1</measure>
    <time_frame>Screening up to study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) assessed by site investigator as per RECIST 1.1</measure>
    <time_frame>Screening up to study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Screening up to study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Advanced Solid Tumours</condition>
  <arm_group>
    <arm_group_label>Treatment group: SHR-A1921</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-A1921</intervention_name>
    <description>Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.</description>
    <arm_group_label>Treatment group: SHR-A1921</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntary participation and written informed consent；&#xD;
&#xD;
          2. Aged 18-75 years (inclusive), males and females;&#xD;
&#xD;
          3. Consents to provide tumor tissue samples;&#xD;
&#xD;
          4. Subjects must have histologically or clinically confirmed advanced and/or metastatic&#xD;
             malignancies for which failure of standard treatment or lack of effective standard&#xD;
             treatment;&#xD;
&#xD;
          5. At least one measurable lesion according to RECIST v1.1;&#xD;
&#xD;
          6. ECOG score of 0-1;&#xD;
&#xD;
          7. Expected survival ≥ 12 weeks;&#xD;
&#xD;
          8. Adequate bone marrow reserve and organ function ；&#xD;
&#xD;
          9. For female patients of childbearing potential or male patients with partners of&#xD;
             childbearing potential who are not sterilized by surgical operations, they are&#xD;
             required to use a medically approved contraceptive measure during the study treatment&#xD;
             period and within 3 months after the end of the study treatment; For female patients&#xD;
             of childbearing potential who are not sterilized by surgical operations, they must&#xD;
             have a negative serum HCG test result within 72 h prior to study enrollment; and they&#xD;
             must not be in the lactation period;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known and untreated central nervous system (CNS) or leptomeningeal metastases;&#xD;
&#xD;
          2. Macrovascular invasion based on imaging;&#xD;
&#xD;
          3. Cancerous ascites, pleural effusion or pericardial effusion with clinical symptoms;&#xD;
&#xD;
          4. Has a history of a second malignancy;&#xD;
&#xD;
          5. History of immunodeficiency disease or organ transplant;&#xD;
&#xD;
          6. Uncontrolled cardiac diseases or symptoms;&#xD;
&#xD;
          7. Has a history of non-infectious ILD/pneumonitis that required steroids, or has current&#xD;
             ILD/pneumonitis;&#xD;
&#xD;
          8. Has a history of active chronic enteritis 6 weeks prior to the initiation of the study&#xD;
             treatment or intestinal obstruction, gastrointestinal perforation 3 months prior to&#xD;
             the initiation of the study treatment;&#xD;
&#xD;
          9. Has a history of Grade≥2 bleeding 4 weeks prior to the initiation of the study&#xD;
             treatment or is current receiving anticoagulation therapy;&#xD;
&#xD;
         10. Subjects with active hepatitis B or active hepatitis C;&#xD;
&#xD;
         11. Subjects who have received systemic anti-tumor treatments 4 weeks prior to the&#xD;
             initiation of the study treatment.&#xD;
&#xD;
         12. Has unresolved toxicities from previous anticancer therapy.&#xD;
&#xD;
         13. Has a history of severe hypersensitivity reactions to either the drug substances or&#xD;
             inactive ingredients of SHR-A1921;&#xD;
&#xD;
         14. Subjects with other potential factors that may affect the study results or result in&#xD;
             the premature discontinuation as determined by the investigator, such as alcoholism,&#xD;
             drug abuse, other serious diseases (including mental illness) requiring concomitant&#xD;
             treatment, serious laboratory abnormalities, or family or social factors that could&#xD;
             affect the safety of the patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Quanren Wang, Ph.D</last_name>
    <phone>86-021-61053363</phone>
    <email>quanren.wang@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Di Zong, MS</last_name>
    <phone>86-010-67166319</phone>
    <email>di.zong@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

